Ph.D., Vice President, R&D, Natera
Bernhard Zimmermann has been a pioneer in the field of cell-free DNA for more than 15 years. At Natera he was the lead scientist in the development of massively multiplex PCR and the market-leading Panorama non-invasive prenatal test (NIPT). More recently, his team has developed multiple workflows for analysis of circulating tumor DNA using fixed and personalized panels. Results of this work were recently published in an article in Nature entitled, “Phylogenetic ctDNA analysis depicts early stage lung cancer evolution”. In August 2017 Natera launched the personalized Liquid Biopsy test, Signatera, for research use only.
Presentation Title and Company Description
Clinical Dx Showcase: Signatera – Personalized Liquid Biopsy for Recurrence Monitoring
Natera is committed to transforming the diagnosis and management of genetic diseases in women’s health and oncology. We are employing our cutting-edge cell-free DNA (cfDNA) testing technology to address the unmet needs of biopharmaceutical companies and researchers, and ultimately to impact cancer care in the clinic.